Mutant p53: A therapeutic target for the treatment of triple-negative breast cancer?

被引：0
|
作者：
Synnott, Naoise C.
Pierce, Aisling
Mullooly, Maeve
Caiazza, Francesco
McGowan, Patricia M.
O'Donovan, Norma
Crown, John
Duffy, Michael J.
机构：
[1] Univ Coll Dublin, Educ & Res Ctr, St Vincents Univ Hosp, Dublin 2, Ireland
[2] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland
[3] Dublin City Univ, Natl Inst Cellular Biotechnol, Mol Therapeut Canc Ireland, Dublin 9, Ireland
[4] Irish Clin Oncol Res Grp, Dublin, Ireland
[5] Mol Therapeut Canc Ireland, Dublin, Ireland
[6] Univ Coll Dublin, Clin Res Ctr, St Vincents Univ Hosp, Dublin 2, Ireland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1118
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1118
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [31] Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers
    Chevaun D Morrison
    Jenny C Chang
    Ruth A Keri
    William P Schiemann
    Cell Death & Disease, 2017, 8 : e2899 - e2899
  • [32] Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions
    Naeimzadeh, Yasaman
    Tajbakhsh, Amir
    Fallahi, Jafar
    HELIYON, 2024, 10 (04)
  • [33] RSK2: a promising therapeutic target for the treatment of triple-negative breast cancer
    My-my Huynh
    Jayanthan, Aarthi
    Pambid, Mary Rose
    Los, Gerrit
    Dunn, Sandra E.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2020, 24 (01) : 1 - 5
  • [34] Immunohistochemical status of p53 as prognostic factor in patients with node negative triple-negative breast cancer
    Bae, S. Y.
    Lee, J. E.
    Lee, S. K.
    Nam, S. J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] Deregulated MicroRNAs involved in P53 Signaling Pathway in Breast Cancer with Focus on Triple-negative Breast Cancer
    Naeimzadeh, Yasaman
    Heidari, Zahra
    Razban, Vahid
    Khajeh, Sahar
    CURRENT MOLECULAR PHARMACOLOGY, 2024, 17
  • [36] cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
    Gaule, Patricia B.
    Crown, John
    O'Donovan, Norma
    Duffy, Michael J.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (09) : 999 - 1009
  • [37] Modulation of the metastatic propensity of triple-negative breast cancer cells harboring p53 mutations
    Morrsion, B. L.
    Tai, J. W.
    Bernal, F.
    CANCER RESEARCH, 2013, 73
  • [38] Differences in prognosis by p53 expression after neoadjuvant chemotherapy in triple-negative breast cancer
    Bae, Soo Youn
    Lee, Jeong Hyeon
    Bae, Jeoung Won
    Jung, Seung Pil
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2020, 98 (06) : 291 - 298
  • [39] Triple-negative breast cancer: investigating potential molecular therapeutic target
    Papa, Anselmo
    Caruso, Davide
    Tomao, Silverio
    Rossi, Luigi
    Zaccarelli, Eleonora
    Tomao, Federica
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (01) : 55 - 75
  • [40] CHK1 AS A THERAPEUTIC TARGET IN TRIPLE-NEGATIVE BREAST CANCER
    Quidville, V.
    Albiges-Sauvin, L.
    Goubar, A.
    Scott, V.
    Andre, F.
    ANNALS OF ONCOLOGY, 2011, 22 : 51 - 52
12345